Etanercept

Etanercept is a recombinant biologic medicine and tumor necrosis factor inhibitor used to treat several chronic inflammatory and autoimmune conditions. It is a soluble tumor necrosis factor receptor fusion protein that binds tumor necrosis factor and reduces its interaction with cell-surface TNF receptors. By decreasing TNF-mediated inflammatory signaling, etanercept can reduce inflammation, pain, swelling, skin lesions, and other disease manifestations depending on the condition being treated. Etanercept is administered by subcutaneous injection and may be given by a healthcare professional or by the patient or caregiver after appropriate training. It is used in adults with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and plaque psoriasis, with additional pediatric indications for selected forms of juvenile idiopathic arthritis and plaque psoriasis. Etanercept may be used alone or together with methotrexate in rheumatoid arthritis according to the clinical setting. Its clinical importance is supported by extensive clinical development and long-term experience in inflammatory rheumatic and dermatologic diseases. Because TNF has an important role in immune defense, treatment requires appropriate screening and monitoring for infections and other immune-related complications.

Etanercept was developed using recombinant DNA technology as a fusion protein combining the extracellular portion of the human TNF receptor with the Fc portion of human immunoglobulin G. The U.S. Food and Drug Administration granted initial approval in 1998 for rheumatoid arthritis, followed by approvals for additional inflammatory conditions and pediatric populations. The European Commission granted marketing authorization for Enbrel in February 2000, with subsequent indication expansions covering rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, and plaque psoriasis. In India, CDSCO records document etanercept approval for marketed use in indications including rheumatoid arthritis and ankylosing spondylitis, with additional regulatory records covering etanercept products. Major clinical development programs included randomized studies in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. Long-term studies and post-marketing safety monitoring have further characterized the benefits and risks of TNF inhibition.

Etanercept is used for several inflammatory conditions in adults and selected pediatric populations. In adults, approved indications include moderately to severely active rheumatoid arthritis, active and progressive psoriatic arthritis, severe active ankylosing spondylitis, severe non-radiographic axial spondyloarthritis with objective evidence of inflammation, and moderate to severe plaque psoriasis, depending on the applicable regulatory authority. In rheumatoid arthritis, etanercept may be used with methotrexate when response to disease-modifying antirheumatic drugs has been inadequate, or as monotherapy when methotrexate is unsuitable. Pediatric indications include selected forms of polyarticular juvenile idiopathic arthritis, juvenile psoriatic arthritis, enthesitis-related arthritis, and chronic severe plaque psoriasis in children of specified ages. Treatment selection depends on disease severity, previous therapy, contraindications, patient age, and the applicable approved indication.

Etanercept is administered by subcutaneous injection. For adults with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis, the usual dose is 50 mg once weekly or 25 mg twice weekly. For adults with plaque psoriasis, 50 mg once weekly is commonly used, while a higher regimen of 50 mg twice weekly may be used for the first 12 weeks under applicable prescribing information before continuing with the maintenance regimen. Pediatric dosing is generally based on body weight and the specific indication. Patients or caregivers may administer the medicine after appropriate training. Treatment duration varies according to the underlying disease and response. Clinical response is generally assessed during the initial months of therapy, and continued treatment should be reconsidered when there is inadequate response. Appropriate storage, handling, and injection-site rotation should be followed according to the product instructions.

Common side effects of etanercept include injection-site reactions, upper respiratory tract infections, headache, and other mild infections or inflammatory symptoms. Injection-site reactions may include redness, itching, swelling, bruising, or pain. Patients may also experience gastrointestinal symptoms, rash, or other nonspecific symptoms. Laboratory abnormalities can occur in some patients, although clinically significant abnormalities are less common. The frequency and severity of adverse effects vary according to the underlying disease, concomitant treatment, age, and individual patient factors. Patients should report persistent fever, recurrent infections, unusual skin changes, breathing difficulties, or other concerning symptoms so that treatment can be assessed and appropriate management provided.

Etanercept carries important warnings regarding serious infections and malignancies. Serious bacterial, viral, fungal, and opportunistic infections, including tuberculosis and invasive fungal infections, have been reported with TNF inhibitors. Treatment should not be started in patients with active serious infection, and patients should be monitored for signs of infection during therapy. Other important risks include hepatitis B virus reactivation, demyelinating disorders, heart failure or worsening of heart failure, serious allergic reactions, hematologic abnormalities, lupus-like syndrome, autoimmune hepatitis, and certain malignancies, including lymphoma and skin cancers. Live vaccines should generally be avoided during treatment. Treatment interruption or discontinuation may be required for serious infection, severe hypersensitivity, significant neurologic complications, or other clinically important adverse events.

Before treatment, clinicians should review the patient's infection history, tuberculosis risk, hepatitis B status, vaccination history, neurological history, heart failure status, malignancy history, and current medicines. Screening for latent tuberculosis should be performed before starting therapy, with appropriate management when indicated. Hepatitis B screening should also be considered before treatment. Patients should be brought up to date with appropriate non-live vaccinations before therapy when possible. Etanercept should generally not be combined with other biologic disease-modifying antirheumatic drugs because of increased risk of serious infections and other adverse effects. Live vaccines should generally not be administered during treatment. Conventional cytochrome P450 drug interactions are not a major concern because etanercept is a biologic protein rather than a small-molecule drug, but concomitant immunosuppressive therapy should be reviewed carefully.

Before initiating etanercept, confirm the diagnosis and approved treatment indication and document baseline disease activity. Complete appropriate screening for tuberculosis and hepatitis B and review vaccination status, infection history, neurological symptoms, heart failure, and malignancy risk. Patients should be taught correct subcutaneous injection technique, storage requirements, safe disposal of needles and devices, and rotation of injection sites. Pharmacists should verify the prescribed dose, formulation, storage conditions, patient training, and concurrent immunosuppressive therapies. During follow-up, monitor treatment response as well as fever, persistent cough, recurrent infections, neurological symptoms, worsening heart failure, skin lesions, and other clinically significant changes. Treatment should be withheld or discontinued when serious infection or other important adverse reactions occur according to the applicable prescribing information. Coordination among rheumatology, dermatology, pediatrics, primary care, and pharmacy teams may be appropriate depending on the indication and patient needs.